Two-year immunogenicity of a pre-exposure rabies vaccination administered as a two-dose schedule

Autor: Laurie Windels, Véronique Naneix-Laroche, Christophe Pasquier, Pierre Delobel, Perrine Parize, Guillaume Martin-Blondel
Přispěvatelé: Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Lyssavirus, épidémiologie et neuropathologie - Lyssavirus Epidemiology and Neuropathology, Institut Pasteur [Paris] (IP), Centre National de Référence de la Rage - National Reference Center Rabies (CNR)
Rok vydání: 2021
Předmět:
Zdroj: Journal of Travel Medicine
Journal of Travel Medicine, 2022, 29 (4), pp.taac029. ⟨10.1093/jtm/taac029⟩
ISSN: 1708-8305
1195-1982
DOI: 10.1093/jtm/taac029⟩
Popis: International audience; Rabies pre-exposure prophylaxis (PrEP) relies on the vaccination of individuals at high risk of exposure, including subpopulations in highly endemic settings with limited access to timely and adequate post-exposure prophylaxis, individuals at occupational risk and travellers who may be at risk of exposure. The latest WHO position paper in 2018 recommends shortening the previous three-dose intramuscular (IM) regimen (Day 0, Day 7 and Day 21) to a two-visit, one-site IM or two-visit, two-sites intra-dermal (ID) administrations, 7 days apart.1 The immunogenicity of these shortened regimens has been assessed mainly in the short term (Days 21 to 35 after the vaccine) or after a booster at 1 year post-vaccination.2,3 In 2019, in the context of severe shortage of the two rabies vaccines available in France for PrEP and post-exposition prophylaxis, a cohort of 228 students from the National Veterinary School of Toulouse (ENVT) received for PrEP this two-visit, one-site IM administrations of rabies vaccine (Rabique Pasteur®) 7 days apart in March 2019 at the vaccination centre of the Toulouse University Hospital, following WHO recommendations. Students were asked to perform a post-vaccination rabies antibody test that was initially planned at 1 year, but was however postponed to May 2021 because of the coronavirus disease 2019 pandemic. Our aim was to assess the long-term immunogenicity of this shortened PrEP regimen. For the purpose of this study, we collected the results of this rabies serology. Participants were included if they had never been vaccinated against rabies before March 2019 (although a serology was not systematically performed to exclude a previous vaccination). The determination of rabies virus neutralizing antibody (RVNA) titer was performed by Rapid Fluorescent Focus Inhibition Test (RFFIT) at the Institut Pasteur of Paris. Students were considered to be protected against rabies (seropositive) if their sera titers were ≥0.5 IU/ml, and seronegative when their sera titers were
Databáze: OpenAIRE
Externí odkaz: